| 摘要 |
FIELD: medicine. ^ SUBSTANCE: method is based on definition of genotypes by polymorphous versions A1166C of gene AGTR1, A-240T and A2350G of gene ACE, C677T of gene MTHFR, T174M of gene AGT, C825T of gene GNB3, VNTR4a/b and G894T of gene NOS3, G 1691 A of gene F5, PLA1/A2 of gene ITGB3, G20210A of gene F2 and evaluation of risk by summing number of points awarded to each genotype. At the same time genotypes of "low" risk of cardiovascular pathology receive 0 points, they include genotypes 1166AA of gene AGTR1, -240AA, 2350AA of gene ACE, 677CC of gene MTHFR, 174TT of gene AGT, 825CC of gene GNB3, VNTR4bb and 894GG of gene NOS3, 1691GG of gene F5, PLA1/A1 of gene ITGB3, 20210GG of gene F2. Genotypes of "medium" risk receive 0.5 points, they include genotypes 1166AC of gene AGTR1, -240AT and 2350AG of gene ACE, 677CT of gene MTHFR, 174TM of gene AGT, 825CT of gene GNB3, VNTR4ab and 894GT of gene NOS3. Genotypes of "high" risk receive 1 point, they include genotypes 1166CC of gene AGTR1, -240TT and 2350GG of gene ACE, 677TT of gene MTHFR, 174MM of gene AGT, 825TT of gene GNB3, VNTR4aa and 894GT of gene NOS3, 1691GA and 1691AA of gene F5, PLA1/A2 and PLA2/A2 of gene ITGB3, 20210GA and 20210AA of gene F2. Risk of cardiovascular diseases is considered "low", if sum of points makes from 0 to 3, "medium" - from 3.5 to 6, "high" - from 6.5 to 11 points. ^ EFFECT: increased accuracy of genetic diagnostics and taking into account interrelation of pathogeny of most cardiovascular diseases. |
